Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Industry News

Study: DCISionRT predicts radiation therapy benefit

Aug. 9, 2018—Prelude Corp. announced that Clinical Cancer Research published results from a large cross-validation study of DCISionRT in patients with ductal carcinoma in situ (Bremer T, et al. Epub ahead of print July 27, 2018. doi:10.1158/1078-0432.CCR-18-0842). The multisite study demonstrated that DCISionRT was a strong predictor of radiation benefit and was able to identify patients with significantly elevated recurrence risk that would be considered low risk by traditional clinical assessment. “The study analyzed the biology and clinical factors of

Beckman releases DxM MicroScan

Aug. 7, 2018—Beckman Coulter announced commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing that uses direct minimum inhibitory concentrations for detection of antimicrobial resistance. The system’s delivery of gold-standard MIC accuracy helps laboratories achieve their operational goals by reducing costs associated with confirmatory testing, the company says. Added workflow enhancements include a new fluid-level sensing technology for added assurance, easy-to-view external LED indicators that show status at a glance, quick bottle

Sysmex, Advanced Instruments offer CSF cell counter

Aug. 6, 2018—Sysmex America and Advanced Instruments announced a partnership that will broaden the Sysmex portfolio with Advanced Instruments’ automated GloCyte cell counter system. The GloCyte system uses a combination of fluorescence, microscopy with digital image analysis, highly specific reagents, and an intelligent counting algorithm to provide accurate counts down to zero for both red blood cell and total nucleated cell in cerebrospinal fluid in adult and pediatric patients. “The addition of GloCyte makes our portfolio of diagnostic analyzers even

FDA approves Cobas HPV Test with SurePath

Aug. 3, 2018—Roche has received FDA approval for the Cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using specimens collected in SurePath preservative fluid. The Roche test is now the only HPV test approved for use as a primary screening test with both SurePath and ThinPrep PreservCyt Solution. It is approved for all of the cervical cancer screening indications supported by guidelines—primary screening in women 25 and older, reflex

MedTest chem assays, hematology analyzer

Aug. 2, 2018—MedTest Dx introduced its BA-800M Clinical Analyzer for general chemistry with a full line of reagents and launched its BC-5390 5-Part Differential Hematology Analyzer at the 2018 American Association for Clinical Chemistry Annual Scientific Meeting, in Chicago. The MedTest Dx BA-800M is a fully automated, discrete random-access chemistry analyzer designed for mid- to large-volume clinical testing laboratories now available with reagents manufactured in the U.S. in a GMP-regulated and ISO 13485-certified environment. The BA-800M has a throughput of

Beckman Coulter, Arkray launch iQ Workcell

Aug. 1, 2018—Beckman Coulter and U.S. Arkray announced a partnership and the launch of the iQ Urinalysis Workcell, which pairs Beckman’s Iris iQ200 Digital Flow Morphology system with the Arkray Aution Max AX-4030 fully automated urine analyzer. The iQ Urinalysis Workcell will be available in the U.S. exclusively through Beckman Coulter; the company will also offer the Aution Max AX-4030 and the Aution Eleven AE-4022 analyzers as standalone solutions. “This partnership integrates our urine chemistry solutions with Beckman Coulter’s urine

FDA clears Siemens’ TnIH assays

July 30, 2018—Siemens Healthineers announced FDA clearance of its High-Sensitivity Troponin I assays (TnIH) for its Atellica IM and Advia Centaur XP/XPT in vitro diagnostic analyzers to aid in the early diagnosis of myocardial infarctions. The high sensitivity of the TnIH assays “offers the ability to detect lower levels of troponin at significantly improved precision at the 99th percentile and detect smaller changes in a patient’s troponin level as repeat testing occurs,” the company said in a statement. Troponin indicates

Qiagen broadens GeneReader applications

July 27, 2018—Qiagen has introduced next-generation sequencing solutions for a range of hereditary diseases on its GeneReader NGS System. The customizable QIAact target enrichment panels enable the analysis of more than 13 hereditary disease groups, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, and universal carrier screening. The solutions integrate the company’s QCI analysis, which includes the Human Gene Mutation Database, a knowledge base containing comprehensive data on inherited disease mutations for genetic and genomic research. “Genetic laboratories are eager

Leica rolls out next-gen research stainer

July 26, 2018—Leica Biosystems introduced the Bond Rx next-generation research stainer. The new system offers greater flexibility when optimizing conditions for a variety of test types including immunofluorescence, immunohistochemistry, fluorescence in situ hybridization, tyramide signal amplification, multiplexing, and other emerging tests. Bond Rx allows users to customize dewax options, choose from six probe application and removal protocols, and select the dispense type from three reagent flow options. Reagents are illuminated and provide clear visual alerts, and the version 6.0 software

Elecsys CSF assays get breakthrough approval

July 25, 2018—The Food and Drug Administration granted breakthrough device designation to Roche’s Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-amyloid (1-42) and phospho-tau concentrations in cerebrospinal fluid in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of dementia. Measuring biomarkers with CSF immunoassays, associated with AD pathology, increases certainty of a diagnosis of AD and can help to evaluate

MARKETPLACE

TRENDING